Breaking News

iosBio Inks Exclusive Vax Platform Pact for COVID-19

OraPro oral delivery vaccine platform technology enables oral administration of thermally-stable, viral vector vaccines.

By: Contract Pharma

Contract Pharma Staff

iosBio, a UK-based biotechnology company developing orally administered vaccines, entered an exclusive worldwide licensing agreement with ImmunityBio, Inc. a US-based immunotherapy company, for iosBio’s OraPro vaccine platform technology currently being investigated in trials of ImmunityBio’s second-gen human Adeno (hAd5) COVID-19 vaccine candidate.   OraPro oral delivery vaccine platform technology enables oral administration of thermally-stable, viral vector vaccines. These vaccine vectors a...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters